Filtered By:
Management: Funding

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 2110 results found since Jan 2013.

A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future
Expert Rev Anti Infect Ther. 2022 Nov 15:1-13. doi: 10.1080/14787210.2022.2142118. Online ahead of print.ABSTRACTINTRODUCTION: Antimicrobial resistance (AMR) is a major threat to global health requiring continuous development of new antimicrobial agents. Antimicrobial research and development (R&D) should be promoted in the pharmaceutical industry and academia to ensure sustainable patient access to new treatment options and reduce the global AMR burden.AREAS COVERED: This review describes the historical challenges in novel antimicrobial drug development in Japan, current national efforts to promote the development, an...
Source: Expert Review of Anti-Infective Therapy - November 11, 2022 Category: Infectious Diseases Authors: Takahisa Ohashi Masahito Nagashima Nobuko Kawai Norio Ohmagari Kazuhiro Tateda Source Type: research

News at a glance: Earth ’s top geological sites, cameras on sharks, and China’s space station
NATURAL HISTORY Science society lists Earth’s top ‘geoheritage’ sites The International Union of Geological Sciences last week marked its 60th anniversary by announcing a list of 100 “geoheritage” sites that have substantially influenced understanding of Earth’s deep history . The global list, released in collaboration with UNESCO, is meant to foster conservation and tourism. The sites include familiar ones, such as the Grand Canyon’s “great unconformity,” a billion-year gap in the rock record erased by erosion. More exotic examples include limestones in Germany that preserve Arc...
Source: Science of Aging Knowledge Environment - November 3, 2022 Category: Geriatrics Source Type: research

Why the U.S. Doesn ’t Have a Nasal Vaccine for COVID-19
The U.S. led the world in quickly developing COVID-19 vaccines—one of the few bright spots in the country’s otherwise criticized response. But while injectable vaccines are effective in protecting people from getting sick with COVID-19, they are less able to block infection. In order to put the pandemic behind us, the world will need a way to stop infections and spread of the virus. That’s where a different type of vaccine, one that works at the places where the virus gets into the body, will likely prove useful. Here, though, the U.S. is losing its edge. In September, India approved a nasal COVID-19 vacc...
Source: TIME: Health - October 31, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Our Third COVID Winter Is Coming. America Isn ’ t Ready.
Our third American COVID winter is at hand. In the months ahead—with students back in school, temperatures dropping, social life moving indoors, and holiday travel commencing—not to mention the emergence of new and increasingly immune-evasive variants—we can count on another seasonal surge of infections and deaths. With the experience of last year’s record-breaking Omicron wave, American leaders should now—at least, in theory—be very well equipped to deal with what’s ahead. Health agencies should be preparing clear, actionable messages on COVID measures for the holiday season. Mask...
Source: TIME: Health - October 20, 2022 Category: Consumer Health News Authors: Martha Lincoln and Nate Holdren Tags: Uncategorized COVID-19 freelance Source Type: news

Our Third COVID Winter Is Coming. America Isn ’ t Ready
Our third American COVID winter is at hand. In the months ahead—with students back in school, temperatures dropping, social life moving indoors, and holiday travel commencing—not to mention the emergence of new and increasingly immune-evasive variants—we can count on another seasonal surge of infections and deaths. With the experience of last year’s record-breaking Omicron wave, American leaders should now—at least, in theory—be very well equipped to deal with what’s ahead. Health agencies should be preparing clear, actionable messages on COVID measures for the holiday season. Mask...
Source: TIME: Health - October 20, 2022 Category: Consumer Health News Authors: Martha Lincoln and Nate Holdren Tags: Uncategorized COVID-19 freelance Source Type: news

U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 35%, hsla(0,...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news

Can long Covid research unlock other great medical mysteries of our time?
Attention and funding for research into mononucleosis, HIV, Lyme, Ebola, Sars and other infections have historically been limited – but long Covid changed thatRead the Guardian ’s new series, Living with long CovidAs the coronavirus grew from a fleeting concern to a full-blown panic, Lili Lim started to hear about people for whom the illness lasted weeks or even months. There were news stories of young people that couldn ’t shake their fatigue or cognitive malaise, of folks who had to quit their job due to debilitating exhaustion.For Lim, the symptoms were frighteningly recognizable.Continue reading...
Source: Guardian Unlimited Science - October 17, 2022 Category: Science Authors: Tik Root Tags: Long Covid Medical research Coronavirus Infectious diseases Science Source Type: news

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00299-5. doi: 10.1016/S2213-2600(22)00299-5. Online ahead of print.ABSTRACTBACKGROUND: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmed health-care systems globally. The Anti-Coronavirus Therapies (ACT) outpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin for prevention of disease progression in community patients with COVID-19.METHODS: The ACT outpatient, open-label, 2 × 2 factorial, randomised, controlled trial, was done at 48 clinical sites in 11 countries. Patients in th...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Wadea M Tarhuni Mohamed Hassany Anna Kontsevaya William Harper Sanjib Kumar Sharma Patricio Lopez-Jaramillo Antonio L D Source Type: research

Evidence suggests pandemic came from nature, not a lab, panel says
The acrimonious debate over the origins of the COVID-19 pandemic flared up again this week with a report from an expert panel concluding that SARS-CoV-2 likely spread naturally in a zoonotic jump from an animal to humans—without help from a lab. “Our paper recognizes that there are different possible origins, but the evidence towards zoonosis is overwhelming,” says co-author Danielle Anderson, a virologist at the University of Melbourne. The report, which includes an analysis that found the peer-reviewed literature overwhelmingly supports the zoonotic hypotheses, appeared in the Proceedings of the Nationa...
Source: ScienceNOW - October 10, 2022 Category: Science Source Type: news

This COVID-19 sleuth is making friends and foes advocating for African science
.news-article__hero--featured .parallax__element{ object-position: 60% 20%; -o-object-position: 60% 20%; } This story was supported by the Pulitzer Center. As Americans began to stir in the early morning hours of Thanksgiving Day 2021, a rapt international press corps was listening as a pony-tailed scientist in South Africa announced the identification of a worrisome new SARS-CoV-2 variant. Tulio de Oliveira, a Brazilian-born bioinformatician, explained that many of the variant’s dozens of mutations might make it more immune evasive and contagious—and that it was spreading “very fast” in South Africa. ...
Source: Science of Aging Knowledge Environment - October 6, 2022 Category: Geriatrics Source Type: research

Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world
In December 2019, an outbreak emerged of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which leads to coronavirus disease 2019 (COVID-19). The World Health Organisation announced the outbreak a global health emergency on 30 January 2020 and by 11 March 2020 it was declared a pandemic. The spread and severity of the outbreak took a heavy toll and overburdening of the global health system, particularly since there were no available drugs against SARS-CoV-2. With an immediate worldwide effort, communication, and sharing of data, large amounts of funding, researchers and pharmaceutical companies immediately fast...
Source: Frontiers in Immunology - October 3, 2022 Category: Allergy & Immunology Source Type: research

Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection
EBioMedicine. 2022 Sep 27:104293. doi: 10.1016/j.ebiom.2022.104293. Online ahead of print.ABSTRACTBACKGROUND: The majority of those infected by ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) during the UK first wave (starting March 2020) did not require hospitalisation. Most had a short-lived mild or asymptomatic infection, while others had symptoms that persisted for weeks or months. We hypothesized that the plasma proteome at the time of first infection would reflect differences in the inflammatory response that linked to symptom severity and duration.METHODS: We performed a nested longitudinal ca...
Source: Atherosclerosis - October 1, 2022 Category: Cardiology Authors: Gabriella Captur James C Moon Constantin-Cristian Topriceanu George Joy Leo Swadling Jenny Hallqvist Ivan Doykov Nina Patel Justyna Spiewak Tomas Baldwin Matt Hamblin Katia Menacho Marianna Fontana Thomas A Treibel Charlotte Manisty Ben O'Brien Joseph M G Source Type: research